Work

Alliance A091404: A phase II study of enzalutamide (NSC# 766085) for patients with androgen receptor-positive salivary cancers.

Year: 2019

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2019.37.15_suppl.6020

Authors: Alan Loh Ho, Nathan R. Foster, Alexander J. Zoroufy, Francis P. Worden, Katharine Andress Rowe Price, Douglas Adkins, Daniel W. Bowles, Hyunseok Kang, Barbara Burtness, Eric Jeffrey Sherman, Roscoe F. Morton, Nora Katabi, Pamela N. Munster, Gary K. Schwartz

Institutions: Memorial Sloan Kettering Cancer Center, Mayo Clinic, U-M Rogel Cancer Center, Washington University in St. Louis, Johns Hopkins University, Sidney Kimmel Comprehensive Cancer Center, Yale Cancer Center, Yale University, University of California, San Francisco, Columbia University Irving Medical Center

Language: English

Topic: Salivary Gland Tumors Diagnosis and Treatment

Subfield: Surgery

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2947440683

Cites:

Cited by: 21

Related to: 10